Skip to main content
. 2021 Feb 24;372:n135. doi: 10.1136/bmj.n135

Table 4.

Reasons for withdrawals by treatment

All withdrawals (n=80) During a placebo period (n=39) During a statin period (n=34) Neither (n=7)
Withdrawal of consent 16 (8) 8 (4) 7 (3.5) 1 (0.5)
 Muscle symptoms* 1 (0.5) 1 (0.5) 0 0
 Non-muscle symptoms* 4 (2) 2 (1) 2 (1) 0
 Not related to drug treatment* 3 (1.5) 1 (0.5) 2 (1) 0
 Switched to statin* 0 0 0 0
 No reason given* 8 (4) 4 (2) 3 (1.5) 1 (0.5)
Intolerable muscle symptoms 32 (16) 13 (6.5) 18 (9) 1 (0.5)
Clinical concern 14 (7) 9 (4.5) 4 (2) 1 (0.5)
 Muscle symptoms* 1 (0.5) 1 (0.5) 0 0
 Non-muscle symptoms* 4 (2) 2 (1) 2 (1) 0
 Not related to drug treatment* 5 (2.5) 3 (1.5) 2 (1) 0
 Switched to statin* 4 (2) 3 (1.5) 0 (0) 1 (0.5)
Other 17 (8.5) 8 (4) 5 (2.5) 4 (2)
 Non-muscle symptoms* 4 (2) 4 (2) 0 0
 Not related to drug treatment* 13 (6.5) 4 (2) 5 (2.5) 4 (2)
Unknown 1 (0.5) 1 (0.5) 0 0

Data are number (%) of participants from 200 participants randomised to a sequence of treatments.

*

Post hoc finer categorisation.